Rheumatoid arthritis (RA) is a specific and chronic systemic autoimmune disease that includes different degrees of joint, extra-articular, and systemic manifestations. The most severe consequences of RA are the destruction of joint structures and lead to disability. The early use of Disease-modifying antirheumatic drugs (DMARDs) at the time of definitive diagnosis is the cornerstone of rheumatoid arthritis treatment strategies. Thanks to advances in molecular biology and genetics, the pathogenesis of rheumatoid arthritis has been clearly defined in the past two decades, and the treatment of RA has made remarkable strides. Several generations of DMARDs have been developed, which are classical DMARDs (Methotrexate), biologics (Tocilizumab), and in the future, the targeted therapy DMARDs (anti-JAK). In addition, the treatment trend of rheumatoid arthritis has changed dramatically. Early detection, early aggressive treatment, “Treatment to target” and early use of classical DMARDs in combination with new biologic drugs to achieve remission as quickly as possible are optimal measures that help change outcomes for patients with rheumatoid arthritis.
Lọc theo danh mục
Lượt truy cập :
20,181,653
Xem toàn văn